Kenox business model is to develop innovative and improved therapies for unmet medical needs and/or for better patient outcomes. We repurpose approved drugs to inhalation route using innovative formulations, devices/drug delivery systems, and thereby enhance therapeutic efficacy and/or decrease adverse effects. Diversified portfolio of 505(b)(2) products are in different phases of development. Our target indications include Asthma/COPD, Insomnia, Lung cancer/adjuvant therapy, Depression, Chorea, Nicotine replacement therapy, and Pulmonary arterial hypertension.
In addition, as part of our short-term strategy, we have developed differentiated OTC and generic products with lower regulatory risk of failures, and currently in negotiations with marketing and manufacturing partners for product launch.
Please reach out to bd@kenoxpharma.us to learn more about Kenox pipeline and partnering opportunities.
